Obesity
Achieving clinically meaningful weight loss and cardiometabolic targets is a key goal in the management of obesity and type 2 diabetes, particularly in people at elevated cardiovascular risk. In this analysis of the phase 3 STEP UP T2D trial, researchers evaluated the extent to which participants treated with semaglutide 7.2 mg, semaglutide 2.4 mg or placebo achieved predefined BMI, waist-to-height ratio and cardiometabolic targets after 72 weeks. In this interview, Prof. Carel le Roux discusses the rationale for assessing these treatment targets, the key findings from the analysis and their implications for the use of higher-dose semaglutide in people with obesity and type 2 diabetes.
Data presented at ENDO 2026 highlighted investigational approaches for difficult-to-control type 2 diabetes and acquired hypothalamic obesity, real-world outcomes with tirzepatide, and wider health impacts of GLP-1-based therapy.
Dr Eric Ravussin discusses REDEFINE 1 findings from ECO 2026, highlighting improvements in physical function and preserved functional strength despite substantial weight loss with the GLP-1/amylin agonist combination CagriSema.
New interim data from OUTSTEP 1 reveal high levels of patient satisfaction with injectable semaglutide and underscore the importance of understanding patient experiences beyond clinical trials. “While still endorsing the ‘my responsibility only’ narrative, we are learning that a new attitude ...
Following ECO 2026, Dr Line Kristin Johnson discusses new evidence supporting structured rapid weight loss programmes, highlighting their potential to improve long-term weight loss, achieve risk-reduction targets and reshape obesity management.
Dr Laurence Dobbie discusses a new European consensus statement highlighting the nutritional, functional and psychological considerations needed to support safe, effective and equitable use of incretin-based therapies in obesity management.
In this interview, Diana Isaacs shares her highlights from the 2026 AACE Annual Meeting, discussing key advances in diabetes management, obesity treatment and diabetes technology, alongside emerging priorities for future endocrinology research and guideline development.
Welcome to the summer 2026 issue of touchREVIEWS in Endocrinology. In this issue, we bring together articles that reflect the evolving complexity of endocrine and metabolic disease, while highlighting the growing importance of patient-centred care, translational science and interdisciplinary management. We ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1RA-based therapies are currently considered to be one of the most attractive classes of medications for managing type 2 diabetes (T2D) because of their impressive weight loss properties, glycated haemoglobin (HbA1c) ...
Urinary lithogenesis processes are activated in patients with obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D). This is a relatively unfamiliar topic among endocrinologists. Beyond the epidemiological evidence accumulated over the recent years, the purpose of this paper is ...
Insulin resistance (IR), a hallmark of various metabolic disorders, represents a diminished responsiveness of target tissues to the actions of insulin, resulting in impaired glucose uptake, dyslipidaemia and endothelial dysfunction.1,2 Worldwide, the prevalence of IR among adults ranges from 15.5% to 46.5%.3–5 ...
Drawing on the experience of expert faculty and emerging leaders who have already navigated many of the early hurdles when embarking on a career in endocrinology, we asked for one piece of career advice to share with those just starting out. Their reflections highlight the importance of curiosity, compassion, adaptability and purpose in building a fulfilling and sustainable career.
GLP-1 receptor agonists have been a standout development this year, reshaping the treatment of type 2 diabetes and obesity. In this expert perspective, Glenn D Braunstein highlights their expanding benefits, from weight loss and cardiometabolic protection to emerging dual- and tri-agonist therapies, while also addressing key challenges as these agents move rapidly into mainstream clinical practice.
In this interview, Dr Iulia Pirga reflects on key advances in endocrinology, persistent challenges in metabolic disease and the growing potential of AI to transform patient care and clinical decision-making.
Post-bariatric weight regain is a major clinical challenge. In the BARI-STEP trial, semaglutide 2.4 mg weekly led to substantial, sustained weight loss and improved cardiometabolic health. Dr Janine Makarondis discusses the findings and the potential of GLP-1 therapy in this patient population.
Dr Sourabh Sharma, a nephrologist and transplant physician at Safdarjung Hospital and Vardhaman Mahaveer Medical College in New Delhi, shares his thoughts on this year’s key advances, the challenges that remain, and the growing impact of AI on nephrology.
ObesityWeek® 2025 highlighted obesity as a chronic, multi-system disease that links cardiovascular, renal, and metabolic health. New data from clinical trials showcased therapies improving weight, blood pressure, and inflammation, signalling a shift toward integrated care where obesity management becomes central to cardiovascular-kidney-metabolic health.
We spoke with Dr Garvey at EASD 2025 to learn more about the mechanism of action of cagrilintide, the design and outcomes of the REDEFINE 1 analysis, and the future directions for this promising therapeutic option.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
